Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M malaria sporozoite challenge study with and without ME-TRAP viral vectors
2016-001265-92Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jun 2016
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of R21/Matrix-M, Matrix M, ChAd63 ME-TRAP and MVA ME-TRAP in Falciparum malaria (PF) and malaria (5 arms), sponsored by University of Oxford. Primary endpoint: Protective efficacy against malaria challenge. Started Jun 2016; status: completed.
02
Drugs
R21/Matrix-MMatrix MChAd63 ME-TRAPMVA ME-TRAP
03
Conditions
Falciparum malaria (PF)malaria
Beyond the preview
Go deeper on 2016-001265-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001265-92.